When something is working extremely well, we should demand very compelling evidence before changing it. I believe that’s why ...

Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...

Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week!

GSK has snagged FDA ap­proval for its 5-in-1 meningo­coc­cal vac­cine, pro­pelling it to a fa­mil­iar po­si­tion: ri­val­ing Pfiz­er.

The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide ...

Cor­bus Phar­ma­ceu­ti­cals re­port­ed en­cour­ag­ing ear­ly-stage re­sults for its Nectin-4 tar­get­ing ADC in var­i­ous types of can­cer, but a lack of re­sponse in cer­tain ...

Johnson & Johnson is set to push for confirmation of a bankruptcy plan next week that would settle a vast majority of cases ...

Renee Wegrzyn has been let go as the head of a federal agency that pursues ambitious ideas to accelerate biomedical ...